Imagine that upwards of 10% or more of your research participants are providing fake answers to the study coordinator. Study subjects that are untruthful about their concurrent participation in another drug trial are far more likely to report inaccurate efficacy results. Professional subjects may report efficacy simply to legitimize their participation for site staff. This false efficacy reporting is detrimental to the active comparator efficacy results and will raise placebo rates. Alternatively, if a research subject is participating in the same study at multiple sites because they fear they may be on placebo or low dose, they may be receiving too large a dose that may result in adverse events. Furthermore, we witness research subjects moving between various clinical trials across different therapeutic indications again ingesting investigational products with unknown interactions with other investigational products. This ultimately affects efficacy rates, placebo rates, and the incidence of adverse events. These issues can result in a clinical trials failure. By using the Verified Clinical Trials research subject database registry to prevent duplicate subjects and professional subjects, you can mitigate these issues.